Group 1 - The company plans to globally offer 41.198 million shares, with 4.12 million shares for Hong Kong and 37.078 million shares for international sale [1] - The subscription period is from September 26 to October 2, with a maximum offer price of HKD 14.75 per share and an entry fee of approximately HKD 7,449.38 for 500 shares [1] - The total expected fundraising amount is HKD 608 million, with a net amount of HKD 525 million, aimed at funding the ongoing R&D, clinical development, and commercialization of inhalation formulation candidates [1] Group 2 - The company is focused on the research, production, and commercialization of inhalation technology and drugs, specifically targeting respiratory diseases [1] - The product portfolio strategically aligns with four of the top ten global inhalation drugs projected for 2024, with total sales revenue of USD 4.1 billion [1] - The company has reported net profits of CNY 31.726 million, CNY 21.088 million, and CNY 12.815 million for the fiscal years 2023, 2024, and the first quarter of 2025, reflecting year-on-year changes of 164.22%, -33.53%, and 108.31% respectively [2]

于2022年、2023年、2024年及截至2024年及2025年3月31日止三个月，集团的收益分别为人民币3.49亿 元、人民币5.56亿元、人民币6.08亿元、人民币1.4亿元及人民币1.36亿元，集团的毛利分别为人民币 2.68亿元、人民币4.58亿元、人民币4.91亿元、人民币1.15亿元及人民币1.08亿元。 智通财经APP讯，长风药业(02652)于2025年9月26日-10月2日招股，拟全球发售4119.8万股H股，其中香 港发售占10%，国际发售占90%;发售价将为每股发售股份14.75港元;每手500股H股，预期H股将于2025 年10月8日(星期三)上午九时正开始在联交所买卖。 集团主要专注于吸入技术及吸入药物的研发、生产及商业化，专注于治疗呼吸系统疾病。集团已开发出 覆盖广泛患者、医学专科及治疗领域的产品组合。于往绩记录期间，集团自国家药品监督管理局(国家 药监局)及美国食品药品监督管理局(FDA)获得六项产品批准并赚取大量销售收益，彰显集团在临床开 发、生产、监管事务及商业化方面的能力。 假设发售价为每股股份14.75港元，集团估计将收取全球发售所得款项净额约5.25亿港元。集团目前拟将 ...